Opus Point Partners Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Opus Point Partners Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,439	Closed	-$753K	–	60
2016 Q1	$753K	Sell	11,439 -4,131	-27%	-$216K	0.58%	39
2015 Q4	$968K	Buy	15,570 +7,689	+98%	+$541K	0.64%	42
2015 Q3	$528K	Sell	7,881 -1,271	-14%	-$104K	0.29%	43
2015 Q2	$890K	Hold	9,152	–	–	0.7%	36
2015 Q1	$855K	Hold	9,152	–	–	0.72%	38
2014 Q4	$814K	Buy	+9,152	New	+$667K	0.81%	37

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Opus Point Partners Management's MACK Position: Q2 2016 in Review

Opus Point Partners Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2016, closing a stake of 11,439 shares — an estimated $753K sold.

Opus Point Partners Management first reported a position in MACK in Q4 2014 and held it in 6 quarters. The position peaked at $968K in Q4 2015. 140 funds tracked by Wall St. Rank hold MACK as of Q2 2016.

Opus Point Partners Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Opus Point Partners Management sold 11,439 Merrimack Pharmaceuticals, Inc. shares in Q2 2016, an estimated $753K.
Opus Point Partners Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 6 quarters.
Opus Point Partners Management's Merrimack Pharmaceuticals, Inc. position peaked at $968K in Q4 2015.
140 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2016.

Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.